Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?

Antibodies against different microbial epitopes are associated with disease phenotype, may be of diagnostic importance and may reflect a loss of tolerance in Crohn's disease (CD). Recently, an association was reported between the presence of these antibodies and mutations in pattern receptor genes. Our aim was to investigate whether mutations in various genes other than NOD2/CARD15 or TLR4 associated with CD (NOD1/CARD4, DLG5 and DEFB1) may influence the presence of antibodies against bacterial proteins and carbohydrates in a Hungarian cohort of CD patients. Three hundred and seventy-six well-characterized, unrelated, consecutive CD patients (male/female: 191/185, age at onset: 29.1 +/- 12.9 years, duration: 7.9 +/- 11.7 years) were investigated. Sera were assayed for anti-Omp, anti-Saccharomyces cerevisiae antibodies (ASCAs) immunoglobulin (Ig) A and IgG, and antibodies against a mannan epitope of S. cerevisiae (gASCA), laminaribioside (ALCA), chitobioside (ACCA), and mannobioside (AMCA). NOD1/CARD4, DLG5 and DEFB1 variants were tested by polymerase chain reaction-restriction fragment length polymorphism, and DEFB1 was genotyped in a subgroup of 160 patients. Detailed clinical phenotypes were determined by reviewing the patients' medical charts. The carriage of DEFB1 20A variant alleles less frequently led to antiglycan positivity compared with patients without (29.6% vs 46.2%, OR: 0.49, 95% CI: 0.25-0.97), regardless of disease location or behavior. Similar tendency was observed for DEFB1 44G (present: 21.6% vs absent: 10.2%, P = 0.06) and ALCA. A gene or serology dosage effect was not observed. However, no association was found between the DEFB1 G52A, DLG5 R30Q, and NOD1/CARD4 E266K variants and any of the serology markers. We found that variants in human beta-defensin 1 gene are inversely associated with antiglycan antibodies, further confirming an important role for innate immunity in the pathogenesis of CD.

[1]  T. Molnár,et al.  New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort , 2008, The American Journal of Gastroenterology.

[2]  Y. Mándi,et al.  Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease , 2008, Scandinavian journal of gastroenterology.

[3]  P. Lakatos,et al.  Smoking in inflammatory bowel diseases: good, bad or ugly? , 2007, World journal of gastroenterology.

[4]  F. Nagy,et al.  NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease. , 2007, Digestive and Liver Disease.

[5]  M. Tremelling,et al.  Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts , 2007, Journal of Medical Genetics.

[6]  G. Veres,et al.  Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients , 2007, Inflammatory bowel diseases.

[7]  P. Rutgeerts,et al.  Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease , 2007, Gut.

[8]  E. Oláh,et al.  Germline MLH1 and MSH2 mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing. , 2007, World journal of gastroenterology.

[9]  K. Van Steen,et al.  New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2007, Gut.

[10]  M. Papp,et al.  Utility of serological markers in inflammatory bowel diseases: gadget or magic? , 2007, World journal of gastroenterology.

[11]  S. Targan,et al.  NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. , 2007, Gastroenterology.

[12]  L. Sandoval-Ramírez,et al.  Association of β-Defensin 1 Single Nucleotide Polymorphisms with Atopic Dermatitis , 2006, International Archives of Allergy and Immunology.

[13]  P. Lakatos.  Recent trends in the epidemiology of inflammatory bowel diseases: up or down? , 2006, World journal of gastroenterology.

[14]  Z. Halpern,et al.  Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. , 2006, Gastroenterology.

[15]  N. Anthonisen,et al.  Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study , 2006, Respiratory research.

[16]  P. Rutgeerts,et al.  DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease. , 2006, Inflammatory bowel diseases.

[17]  P. Lakatos,et al.  Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? , 2006, World journal of gastroenterology.

[18]  E. Louis,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[19]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[20]  K. Fellermann,et al.  Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn’s disease , 2005, Journal of leukocyte biology.

[21]  H. Drummond,et al.  Sero-Reactivity to Microbial Components in Crohn's Disease Is Associated with Disease Severity and Progression, but not NOD2/CARD15 Genotype , 2004, The American Journal of Gastroenterology.

[22]  A. Bousvaros,et al.  Serologic Testing with ANCA, ASCA, and Anti-OmpC in Children and Young Adults with Crohn's Disease and Ulcerative Colitis: Diagnostic Value and Correlation with Disease Phenotype , 2004, The American Journal of Gastroenterology.

[23]  M Schwab,et al.  NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression , 2004, Gut.

[24]  B. Sands,et al.  A male with a pelvic mass , 2004, Gut.

[25]  Thomas Lengauer,et al.  Genetic variation in DLG5 is associated with inflammatory bowel disease , 2004, Nature Genetics.

[26]  P. Lakatos,et al.  Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. , 2003, World journal of gastroenterology.

[27]  T. Ganz.  Defensins: antimicrobial peptides of innate immunity , 2003, Nature Reviews Immunology.

[28]  M. Weichenthal,et al.  Inducible and Constitutive &bgr;-Defensins Are Differentially Expressed in Crohn's Disease and Ulcerative Colitis , 2003, Inflammatory bowel diseases.

[29]  S. Foster,et al.  An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid , 2003, Nature Immunology.

[30]  T. C. White,et al.  Single-Nucleotide Polymorphisms (SNPs) in Human β-Defensin 1: High-Throughput SNP Assays and Association with Candida Carriage in Type I Diabetics and Nondiabetic Controls , 2003, Journal of Clinical Microbiology.

[31]  P. Rutgeerts,et al.  Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. , 2001, Gastroenterology.

[32]  P. Rutgeerts,et al.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[33]  S. Targan,et al.  Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[34]  S. Targan,et al.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role , 1998, Gut.

[35]  R. Lehrer,et al.  Widespread expression of beta‐defensin hBD‐1 in human secretory glands and epithelial cells , 1996, FEBS letters.

[36]  M. Kerr,et al.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. , 1988, BMJ.

[37]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.